Telix Pharmaceuticals, (ASX: TLX, Telix, the Company) a biopharmaceutical company headquartered in Melbourne, Australia, announced today plans to add 20 executive-level and administrative positions to its US headquarters in Fishers, Indiana. Telix Pharmaceuticals US established its operations for radiopharmaceutical development and manufacturing in Fishers in early 2020. Telix US headquarters is located at 12 Municipal Drive, Suite 330, Fishers, Indiana.
“Establishing our US headquarters in Fishers, Indiana is an important step in our strategy for global expansion. We’re thrilled to be able to find a city that has the manufacturing infrastructure to support our operational expansion in the United States,” said Dr. Bernard Lambert, President Telix Americas. “We are excited for Telix’s future as we advance our pipeline of diagnostic and therapeutic products, and we will continue to implement our strategy that includes growing our team in the United States.”
Telix participated in a late-cycle review meeting with the U.S. Food and Drug Administration (FDA) last month regarding a New Drug Application (NDA) for the Company’s prostate cancer imaging investigational product Illuccix®. Telix anticipates FDA approval of Illuccix® by the end of 2021.
“We are well-positioned to lead on radiopharmaceutical distribution because of our central location and the time-sensitivity around patient access,” said Fishers Mayor Scott Fadness. “With the recent surge of life science cluster development in Fishers, we are excited to welcome Telix to the Fishers community.”
Telix is currently recruiting for open positions and encourages qualified individuals to review available job opportunities here.
“Telix had 49 other options to establish its U.S. headquarters, and we couldn’t be more grateful they chose Indiana to put down new roots,” said Jim Staton, SVP and Chief Business Development Officer for the Indiana Economic Development Corporation. “We’re proud to have them join Indiana’s thriving life sciences sector and look forward to supporting their growth as they provide high-quality jobs for Hoosiers.”
The IEDC offered Telix Pharmaceuticals (US) Inc. up to $500,000 in conditional tax credits based on the company’s job creation plans. These incentives are performance-based, meaning the company is eligible to claim incentives once Hoosiers are hired.
Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia, with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.
Telix’s lead investigational product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA1, and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA).2 Telix is also progressing marketing authorisation applications for Illuccix® in the European Union3 and Canada.4 None of Telix’s products have received a marketing authorisation in any jurisdiction.